clobetasol and Breast-Neoplasms

Twenty-three patients with chronic idiopathic urticaria and 3 patients with urticaria pigmentosa received a 2-week treatment with daily application of potent topical steroid using plastic occlusion. Seventy per cent of the chronic urticaria patients had a statistically significant, immediate response, which, however, did not last until the final evaluation after 1.5 years. Relapse occurred after on average 3 weeks, but 39% reported less severity. The 3 patients with urticaria pigmentosa remained free from attacks for 6 to 9 months, after which they gradually relapsed. Two women were diagnosed during the follow-up period to have a carcinoma of the breast, and one patient developed systemic lupus erythematosus.

Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Breast Neoplasms; Chronic Disease; Clobetasol; Female; Follow-Up Studies; Glucocorticoids; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Occlusive Dressings; Recurrence; Retrospective Studies; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome; Urticaria; Urticaria Pigmentosa

Radiation dermatitis often presents as a problem for patients and radiotherapists during treatment. Topical corticosteroids have been shown to have an anti-inflammatory effect in the treatment of many skin diseases and are commonly prescribed during a course of radiation treatment. A comparison of two different steroid creams, 1% hydrocortisone cream and 0.05% clobetasone butyrate (Eumovate), in a double blind trial was carried out in 54 patients undergoing radiation therapy for breast cancer. 'The cream' was administered when patients reached a given dose of 2000 rad (or earlier if required) whether a skin reaction was present or not. The aim of the trial was to evaluate the general effectiveness of steroids in controlling radiation dermatitis and whether one type of cream was superior to the other. The majority of patients using either cream derived benefit in its soothing effect. There was, however, a significant difference in the intensity of reactions seen, patients using clobetasone butyrate developed more severe radiation reactions despite both groups having similar radiation doses. The possibility of two differing populations having different responses to radiation is discussed as is the 'breakthrough phenomenon' described in the literature. It is concluded that neither cream should be used as first choice in the control of radiation dermatitis.

Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Breast Neoplasms; Clinical Trials as Topic; Clobetasol; Double-Blind Method; Female; Humans; Hydrocortisone; Male; Radiodermatitis; Radiotherapy; Radiotherapy Dosage; Random Allocation; Time Factors

Pertuzumab and trastuzumab are monoclonal antibody inhibitors targeting human epidermal growth factor receptor 2 (HER-2) and are increasingly being utilised in the management of HER2-positive breast cancer, having been demonstrated to improve progression-free survival in conjunction with docetaxel. We present a rare presentation of a lichenoid drug eruption, in an annular atrophic variant, in a 35-year-old woman after initiation of HER2-inhibitor (pertuzumab and trastuzumab) therapy for metastatic breast cancer.

Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Clobetasol; Female; Glucocorticoids; Humans; Lichen Planus; Receptor, ErbB-2; Trastuzumab

Topics: Administration, Topical; Aged; Biopsy; Breast Neoplasms; Clobetasol; Female; Glucocorticoids; Humans; Lupus Erythematosus, Discoid; Piperazines; Protein Kinase Inhibitors; Pyridines; Treatment Outcome

We report the case of a 59-year-old woman with type A regional lymphomatoid papulosis (LyP) that was localized to the left breast, a cutaneous area that had received radiotherapy for treatment of a carcinoma of the breast 5 years prior. This report is a rare example of regional LyP with all lesions located in an area of prior radiotherapy.

Topics: Biopsy; Breast; Breast Neoplasms; Clobetasol; Dermatologic Agents; Diagnosis, Differential; Female; Humans; Lymphomatoid Papulosis; Methotrexate; Middle Aged; Skin; Skin Neoplasms; Treatment Outcome

Lichen sclerosus is a commonly misdiagnosed disease that is characterized by thinned, hypopigmented, crinkled skin that often forms a figure-eight shape around the vaginal and anal openings. We present a case of advanced lichen sclerosus in a 53-year-old female patient prescribed a nonsteroidal aromatase inhibitor after the excision of a breast cancer tumor. We present a diagnostic approach to lichen sclerosus by recognizing its common figure-eight pattern, and we review the known causes and treatment of lichen sclerosus. Research has shown that lichen sclerosus is more common in low estrogen states, and thus it is logical that aromatase inhibitors could increase a patient's risk for developing this disease. We therefore propose that all patients prescribed aromatase inhibitors undergo regular vulvo-vaginal exams to rule out lichen sclerosus and other hypoestrogen-related vulvo-vaginal problems.

Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clobetasol; Drug Eruptions; Female; Glucocorticoids; Humans; Middle Aged; Nitriles; Triazoles; Vulvar Lichen Sclerosus

Topics: Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clobetasol; Combined Modality Therapy; Erythema; Female; Follow-Up Studies; Hand Dermatoses; Humans; Immunohistochemistry; Leg Dermatoses; Middle Aged; Severity of Illness Index; Treatment Outcome

Topics: Administration, Topical; Anti-Inflammatory Agents; Breast Neoplasms; Clobetasol; Constriction, Pathologic; Fatal Outcome; Female; Glucocorticoids; Humans; Middle Aged

We describe a 54-year-old woman who developed right breast morphea after radiotherapy following a lumpectomy for infiltrating lobular carcinoma. Skin biopsy confirmed the histological features of morphea. Treatment was initiated with both topical and intralesional steroid, resulting in marked improvement. Morphea following radiotherapy is an infrequently recognized phenomenon. However, when diagnosed early it may be effectively managed with local steroid treatment.

Topics: Administration, Topical; Anti-Inflammatory Agents; Breast Neoplasms; Carcinoma, Lobular; Clobetasol; Combined Modality Therapy; Female; Glucocorticoids; Humans; Middle Aged; Radiation Injuries; Scleroderma, Localized

The treatment of granuloma annulare is still unsatisfactory. A number of topical and systemic therapies have been tried, some of which can improve the condition, but serious side effects are possible with those reported so far. We treated a patient with disseminated granuloma annulare by local application of a vitamin E emulsion and achieved a marked improvement within as little as 12 days.

Topics: Administration, Oral; Administration, Topical; Aged; Aged, 80 and over; Breast Neoplasms; Clobetasol; Drug Therapy, Combination; Female; Granuloma; Humans; Paraneoplastic Syndromes; Skin Diseases; Vitamin E